Poly-ICLC Prostate Cancer Vaccine

Project Description

Novel neoadjuvant 'autovaccination' strategy prior to radical prostatectomy in patients with intermediate and high-risk prostate cancer

Hypothesis: Injection of poly-ICLC, a double-stranded RNA "viral mimic" danger signal, directly into an intact primary prostate tumor, plus "booster" injections administered intra-muscularly (IM), will generate a local and systemic anti-tumor immune response.

Potential to favorably modulate the tumor microenvironment, impact micro-metastatic disease, improve local and systemic anti-tumor immune responses and improve oncological outcomes.

Trial Design

  • Pilot
  • Phase I
  • Clinical Trial
  • Single Center
  • Neoadjuvant Immunotherapy
  • IT + IM poly-ICLC
  • 2 phases
  • Indication: Patients with intermediate and high-risk prostate cancer undergoing radical prostatectomy as the definitive treatment.

Primary Objectives

  • Determine safe dosing frequency
  • Determine feasibility

Secondary Objectives

  • Determine local and systemic immune responses
  • Positive surgical margin rate
  • Biochemical Recurrence rate at 1, 2 and 5 year

Learn More

Tumor Microenvironment

Tumor Microenvironment

Is it possible to develop a vaccine that would help patients develop an immune response to prosate cancer?

Radio Hystopathological Correlation

The potential role of prostate MRI has in recent years expanded significantly, and there is great hope that mpMRI can help address two major problems encountered when treating prostate cancer.


Poly-ICLC Prostate Cancer Vaccine

Primary Cell Cultures Care

Primary Cell Cultures as Models of Prostate Cancer Development

Inflammation & Prostate Cancer

Inflammation and its impact on Prostate Cancer Aggressiveness

GU Immunotherapy

GU Immunotherapy

Schedule Your Appointment